The concept of gene therapy arose during the 1960s and early 1970s. Rogers and Pfuderer
1 carried out the first genetic modification of a virus (Tobacco mosaic virus [TMV]), and …

Lentiviral vectors (LVs) play an important role in gene therapy and have proven successful
in clinical trials. LVs are capable of integrating specific genetic materials into the target cells …

The regenerative capacity of neurons is limited in the central nervous system (CNS), with
irreversible neuronal loss upon insult. In contrast, microglia exhibit extraordinary capacity for …

Lentiviral vectors have been developed and used in multiple gene and cell therapy
applications. One of their main advantages over other vectors is the ability to integrate the …

HIV-1 derived lentiviral vector is an efficient transporter for delivering desired genetic
materials into the targeted cells among many viral vectors. Genetic material transduced by …

Gene targeting is progressively becoming a realistic therapeutic alternative in clinics. It is
unknown, however, whether this technology will be suitable for the treatment of DNA repair …

Lentiviral vectors have demonstrated promising results in clinical trials that target cells of the
hematopoietic system. For these applications, they are the vectors of choice since they …

Microglia contribute to pathophysiology at all stages of multiple sclerosis. Colony‐
stimulating factor‐1 (CSF1) is crucial for microglial proliferation and activation. In this study …

Spinal muscular atrophy (SMA) is a neuromuscular disease particularly characterised by
degeneration of ventral motor neurons. Survival motor neuron (SMN) 1 gene mutations …

The present study investigates the endogenous expression of Suppressor of Cytokine
Signaling-3 (SOCS3) after spinal cord injury (SCI) and its effect on SCI-induced cell death in …